New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 20, 2012
10:00 EDTGMCR, ZIP, RIMM, JOY, AXL, MRK, WFM, PNR, EXPE, AKS, IHG, SIVB, PENN, ADMOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AK Steel (AKS) upgraded to Neutral from Sell at Goldman... American Axle (AXL) upgraded to Hold from Underperform at Jefferies... Archer Daniels (ADM) upgraded to Outperform from Market Perform at BMO Capital... Expedia (EXPE) upgraded to Equal Weight from Underweight at Barclays... Joy Global (JOY) upgraded to Market Perform from Underperform at BMO Capital... Penn National (PENN) upgraded to Neutral from Sell at Goldman... Pentair (PNR) upgraded to Outperform from Neutral at RW Baird... Research in Motion (RIMM) upgraded to Hold from Underperform at Jefferies... SVB Financial (SIVB) upgraded to Buy from Neutral at Citigroup... Whole Foods (WFM) upgraded to Buy from Neutral at Goldman... Zipcar (ZIP) upgraded to Buy from Neutral at Goldman... Intercontinental Hotels (IHG) upgraded to Overweight from Equal Weight at Barclays... Merck (MRK) upgraded to Buy from Neutral at MKM Partners... Green Mountain (GMCR) upgraded to Buy from Neutral at SunTrust.
News For AKS;AXL;ADM;EXPE;JOY;PENN;PNR;RIMM;SIVB;WFM;ZIP;IHG;MRK;GMCR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 23, 2015
07:08 EDTPENNPenn National upgraded at BofA/Merrill
As previously reported, BofA/Merrill upgraded Penn National to Buy from Neutral. The firm views Penn National as the regional stock to own for a segment recovery and notes January 2015 gross gaming revenues had the biggest increase since 2006 and February is tracking strong. This, and improving low end consumer commentary at other operators and easy comps, makes risk-reward more favorable. Price target raised to $20 from $17.
07:04 EDTMRKMerck, NGM Biopharmaceuticals announce multi-year collaboration
NGM Biopharmaceuticals and Merck announced they have entered into a multi-year collaboration to research, discover, develop and commercialize novel biologic therapies across a wide range of therapeutic areas. This agreement will become effective upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The collaboration includes multiple drug candidates currently in preclinical development at NGM, including NP201, which is being evaluated for the treatment of diabetes, obesity and nonalcoholic steatohepatitis. NGM will lead the research and development of the existing preclinical candidates and have the autonomy to identify and pursue other discovery stage programs at its discretion. Merck will have the option to license all resulting NGM programs following human proof of concept trials. If Merck exercises this option, Merck will lead global product development and commercialization for the resulting products, if approved. Under the terms of the agreement, Merck will make an upfront payment to NGM of $94M and will purchase a 15 percent equity stake in NGM for $106M at a price per share that represents a 20% premium to NGMs most recent financing. Merck will commit up to $250M to fund all of NGMs efforts under the initial five-year term of the collaboration, with the potential for additional funding if certain conditions are met. Prior to Merck initiating a Phase 3 study for a licensed program, NGM may elect to either receive milestone and royalty payments or, in certain cases, to co-fund development and participate in a global cost and revenue share arrangement of up to 50%. The agreement also provides NGM with the option to participate in the co-promotion of any co-funded program in the United States. Merck will have the option to extend the research agreement for two additional two-year terms.
06:22 EDTPENNPenn National upgraded to Buy from Neutral at BofA/Merrill
Subscribe for More Information
06:14 EDTWFMWhole Foods to host investor meeting
Investor meeting to be held on February 27 at 9 am. Webcast Link
February 20, 2015
11:07 EDTGMCRKeurig Green Mountain spikes higher, levels to watch
Subscribe for More Information
10:49 EDTGMCRGreen Mountain Coffee calls active on renewed takeover chatter
Subscribe for More Information
10:42 EDTGMCRRumor: Keurig Green Mountain moves up on renewed takeover chatter
Shares of Keurig Green Mountain (GMCR) are moving higher on renewed speculation Coca-Cola (KO) may acquire the rest of the company.
07:40 EDTEXPEExpedia price target raised to $102 from $91 at UBS
Subscribe for More Information
07:08 EDTMRKAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
05:18 EDTEXPEStocks with implied volatility below IV index mean; EXPE TRIP
Stocks with implied volatility below IV index mean; Expedia (EXPE) 28, TripAdvisor (TRIP) 33 according to iVolatility.
February 19, 2015
09:35 EDTWFMOption volume leaders
Option volume leaders: AAPL TSLA TWTR MCD WMT PBR SPWR WFM GILD FB SCTY according to Track Data.
09:02 EDTGMCRKeurig Green Mountain reiterates FY15 EPS view of growth of mid-single digits
Subscribe for More Information
08:38 EDTMRKNewLink reports clinical development milestone achieved with Merck for rVSV-EBOV
NewLink Genetics (NLNK) announced that it had received notification from Merck (MRK) that the milestone event specified in the license and collaboration agreement between the two companies relating to the further development of the rVSV-EBOV, Ebola, vaccine candidate had been achieved. Under the terms of the agreement, NewLink Genetics will receive a payment of $20M in connection with the achievement of the milestone. The milestone pertains to the initiation of a key clinical trial for the vaccine.
07:17 EDTEXPEMaxim to hold a bus tour
Internet/Tech Bus Tour travels throughout Seattle, Washington to various with various industry companies on February 19.
05:34 EDTEXPEStocks with implied volatility below IV index mean; EXPE BBRY
Subscribe for More Information
February 18, 2015
12:25 EDTWFMWhole Foods February weekly volatility at 30 into investor conference
Whole Foods February call option implied volatility is at 33, February weekly is at 29, March is at 24, April is at 23, August is at 22; compared to its 26-week average of 30 according to Track Data, suggesting non-directional near term price movement into a February 26-27 investor conference.
10:54 EDTJOYJoy Global says reducing cost curve is company's priority for customers
Joy Global says focused on growing service business. Looking to accelerate savings on service business for 2015. Company focuses on life cycle management of equipment. Joy Global developing new products in service sector to allow customers to reduce costs. Sees opportunity in tough market to build service business. Seeing better visibility on rebuilds. Comments taken from Barclays Capital Industrial Select Conference.
10:26 EDTJOYJoy Global backs FY15 EPS view $3.10-$3.50, consensus $3.21
Backs FY15 revenue view $3.6B$3.8B, consensus $3.65B. Guidance taken from slides prepared for Barclays Industrial Select Conference.
07:59 EDTWFMWhole Foods recommended ahead of investor conference at Morgan Stanley
Subscribe for More Information
07:07 EDTJOYBarclays to hold a conference
Industrial Select Conference is being held in Miami on February 18-19.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use